Kuo, J.S.-H.; Chang, C.-Y.; Chang, S.-C.; Wei, Y.-F.; Chen, C.-Y.
Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan. Curr. Oncol. 2025, 32, 36.
https://doi.org/10.3390/curroncol32010036
AMA Style
Kuo JS-H, Chang C-Y, Chang S-C, Wei Y-F, Chen C-Y.
Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan. Current Oncology. 2025; 32(1):36.
https://doi.org/10.3390/curroncol32010036
Chicago/Turabian Style
Kuo, Jerry Shu-Hung, Cheng-Yu Chang, Shih-Chieh Chang, Yu-Feng Wei, and Chung-Yu Chen.
2025. "Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan" Current Oncology 32, no. 1: 36.
https://doi.org/10.3390/curroncol32010036
APA Style
Kuo, J. S.-H., Chang, C.-Y., Chang, S.-C., Wei, Y.-F., & Chen, C.-Y.
(2025). Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan. Current Oncology, 32(1), 36.
https://doi.org/10.3390/curroncol32010036